These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3886972)

  • 1. [Graft vs host reaction and graft vs host diseases].
    Sakagami K; Orita K
    Nihon Rinsho; 1985 Jan; 43(1):97-103. PubMed ID: 3886972
    [No Abstract]   [Full Text] [Related]  

  • 2. Graft-versus-host disease: a surge of developments.
    Riddell SR; Appelbaum FR
    PLoS Med; 2007 Jul; 4(7):e198. PubMed ID: 17622190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What determines who develops graft-versus-host disease: the graft or the host (or both)?
    Gale RP; Horowitz MM; Butturini A; Barrett AJ; Kolb HJ
    Bone Marrow Transplant; 1992 Aug; 10(2):99-102. PubMed ID: 1525613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Graft vs. host disease and graft vs. leukemia/tumor effect].
    Okamoto S
    Nihon Rinsho; 2003 Sep; 61(9):1484-7. PubMed ID: 14515713
    [No Abstract]   [Full Text] [Related]  

  • 5. Possibility of three distinct and separable components to fatal graft-vs-host reaction.
    Okunewick JP; Meredith RF; Raikow RB; Buffo MJ; Jones DL
    Exp Hematol; 1982 Mar; 10(3):277-91. PubMed ID: 7040093
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of immunosuppressive drugs for prevention of graft-v-host disease after human HLA matched bone marrow transplantation.
    Gluckman E; Devergie A; Lokiec F; Traineau R; Cosset JM; Lemercier N; Varrin F; Cavazzana M; de Castro H; Meletis J
    Transplant Proc; 1987 Dec; 19(6 Suppl 7):61-5. PubMed ID: 3321648
    [No Abstract]   [Full Text] [Related]  

  • 7. Effector cells of lethal graft-versus-host disease (GVHD) in nude mice.
    Uenaka A; Mieno M; Kuribayashi K; Shiku H; Nakayama E
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3031-2. PubMed ID: 2784924
    [No Abstract]   [Full Text] [Related]  

  • 8. Human graft-versus-host disease.
    Parkman R
    Immunodefic Rev; 1991; 2(4):253-64. PubMed ID: 2059433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-lymphocytes are necessary for fatal graft vs host disease after small bowel transplantation.
    Wallander J; Läckgren G; Tufveson G
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2896-7. PubMed ID: 2784920
    [No Abstract]   [Full Text] [Related]  

  • 10. Incidence of anti-host cytotoxic and proliferative T cell responses after HLA-identical bone marrow transplantation (BMT).
    van Els C; Bakker A; Zwaan F; van Rood JJ; Goulmy E
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2987-8. PubMed ID: 2468249
    [No Abstract]   [Full Text] [Related]  

  • 11. Dissociating graft-vs-host disease from the graft-vs-leukemia effect of allogeneic T cells: the potential role of IL-2.
    Sykes M
    Bone Marrow Transplant; 1992; 10 Suppl 1():1-4. PubMed ID: 1521080
    [No Abstract]   [Full Text] [Related]  

  • 12. Fate of donor T cells in systemic graft-versus-host reaction.
    Matsubayashi Y; Kuribayashi K; Masuda T; Uchino H
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3036-8. PubMed ID: 2565066
    [No Abstract]   [Full Text] [Related]  

  • 13. [Graft versus host reaction and hybrid resistance in experimental models and clinical practice].
    Clerici M; Villa ML; Clerici E
    Boll Ist Sieroter Milan; 1988; 67(3):177-96. PubMed ID: 3072013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Graft-versus-host disease (author's transl)].
    Gratwohl A
    Schweiz Rundsch Med Prax; 1982 Jan; 71(4):129-31. PubMed ID: 7041107
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens.
    Krenger W; Snyder K; Smith S; Ferrara JL
    Transplantation; 1994 Dec; 58(11):1251-7. PubMed ID: 7992370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-versus-host disease associated T helper cell responses specific for minor histocompatibility antigens are mainly restricted by HLA-DR molecules.
    van Els CA; Zantvoort E; Jacobs N; Bakker A; van Rood JJ; Goulmy E
    Bone Marrow Transplant; 1990 Jun; 5(6):365-72. PubMed ID: 2142441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate.
    Tollemar J; Ringdén O; Heimdahl A; Lönnqvist B; Sundberg B
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):470-9. PubMed ID: 3291283
    [No Abstract]   [Full Text] [Related]  

  • 18. Graft-vs-leukemia following bone marrow transplantation: a model of immunotherapy in man.
    Butturini A; Bortin MM; Seeger RC; Gale RP
    Prog Clin Biol Res; 1987; 244():371-90. PubMed ID: 3310000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines in GvH and GvL.
    Holler E; Kolb HJ; Eissner G; Wilmanns W
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S3-6. PubMed ID: 9916621
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclosporine-induced syngeneic graft-versus-host disease: assessment of T cell differentiation.
    Hess AD; Vogelsang GB; Heyd J; Beschorner WE
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2683-6. PubMed ID: 3547947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.